India, June 2 -- "Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients. Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of COVID-19 patients."

- Dilip Shanghvi, Managing Director, Sun Pharma, Mumbai

Published by HT Digital Content Services with permission from BioSpectrum India....